Аденомиоз: от научных открытий к практическим аспектам назначения медикаментозной терапии

1. Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. С.-Пб.: Эко-Вектор, 2017. 615 с.

2. Garcia L., Isaacson K. Adenomyosis: review of the literature. Journal of minimally invasive gynecology. 2011; 18(4): 428–37. doi:10.1016/j.jmig.2011.04.004
3. Zhang Q., Duan J., Liu X., Guo S.W. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016; 428: 1–16. doi:10.1016/j.mce.2016.03.015
4. Cai X., Shen M., Liu X., Nie J. The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. Reprod Sci. 2019; 26(3): 377–85. doi:10.1177/1933719118773490.
5. Avtanski D., Garcia A., Caraballo B., Thangeswaran P., Marin S., Bianco J., et al. In vitro effects of resistin on epithelial to mesenchymal transition (EMT) in MCF-7 and MDA-MB-231 breast cancer cells - qRT-PCR and Westen blot analyses data. Data Brief. 2019; 25: 104118. doi: 10.1016/j.dib.2019.104118.
6. Li Y., Zhang Q., Liu F., Zhang Z., Zou Y., Yang B., et al. Inhibition of formin like 2 promotes the transition of ectopic endometrial stromal cells to epithelial cells in adenomyosis through a MET-like process. Gene. 2019; 710: 186–92. doi: 10.1016/j.gene.2019.06.003.
7. Qi S., Zhao X., Li M., Zhang X., Lu Z., Yang C., et al. Aberrant expression of Notch1/numb/snail signaling, an epithelial mesenchymal transition related pathway, in adenomyosis. Reprod Biol Endocrinol. 2015; 13: 96. doi: 10.1186/s12958-015-0084-2.
8. Luft F.C. Targeting epithelial-mesenchymal transition. J Mol Med. 2015; 93(7): 703–5. doi: 10.1007/s00109-015-1302-2.
9. Cho E.S., Kang H.E., Kim N.H., Yook J.I. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res. 2019; 42(1): 14–24. doi: 10.1007/s12272-018-01108-7.
10. Greening D.W., Gopal S.K., Mathias R.A., Liu L., Sheng J., Zhu H.J., et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol. 2015; 40: 60–71. doi: 10.1016/j.semcdb.2015.02.008
11. Papageorgis P. TGFbeta Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015; 2015: 587193. doi: 10.1155/2015/587193
12. Khan K.N., Kitajima M., Hiraki K., Fujishita A., Nakashima M., Masuzaki H. Involvement of hepatocyte growth factor-induced epithelial-mesenchymal transition in human adenomyosis. Biol Reprod. 2015; 92(2): 35. doi:10.1095/biolreprod.114.124891.
13. Ding D., Liu X., Duan J., Guo S.W. Platelets are an unindicted culprit in the development of endometriosis: clinical and experi- mental evidence. Hum Reprod. 2015; 30(4): 812–32. https://doi.org/10.1093/humrep/dev025
14. Liu X., Shen M., Qi Q., Zhang H., Guo S.W. Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis. Hum Reprod. 2016; 31(4): 734–49. doi: 10.1093/humrep/dew018.
15. Gonzalez D.M., Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7: 8. doi: 10.1126/scisignal.2005189.
16. Parasuraman P., Mulligan P., Walker J.A., et al. Interaction of p190A RhoGAP with eIF3A and other translation preinitiation factors suggests a role in protein biosynthesis. J Biol Chem. 2017; 292(7): 2679–89.
17. Cai X., Shen M., Liu X., Guo S.W. Reduced Expression of Eukaryotic Translation Initiation Factor 3 Subunit e and Its Possible Involvement in the Epithelial-Mesenchymal Transition in Endometriosis. Reprod Sci. 2018; 25(1): 102–9. doi: 10.1177/1933719117702248.
18. Huang T.S., Chen Y.J., Chou T.Y., Chen C.Y., Li H.Y., Huang B.S., Tsai H.W., et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med. 2014; 18(7): 1358–71. doi:10.1111/jcmm.12300.
19. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertility and sterility. 2018; 109(3): 406–17. https://doi.org/10.1016/j.fertnstert.2018.01.032

20. Рухляда Н.Н., Крылов К.Ю., Бирюкова Е.И. Органосохраняющие операции при аденомиозе. Акушерство и гинекология. 2019; 5: 86–9.

21. Цхай В.Б., Микаиллы Г.Т., Костарева О.В., Каплунов В.А., Руф Р.Р. Беременность и роды после радикальной аденомиомэктомии и метропластики по методике Хисао Осада у женщин с диффузным аденомиозом, ассоциированным с бесплодием. Российский вестник акушера-гинеколога. 2019; 19(2): 63–7.

22. Kishi Y., Yabuta M., Taniguchi F. Who will benefit from uterus-sparing surgery in adenomyosis-associated subfertility? Fertil steril. 2014; 102(3): 802–7. https://doi.org/10.1016/j.fertnstert.2014.05.028
23. Sizzi O., et al. Italian multicenter study on complications of laparoscopic myomectomy. J minimal invas gynecol. 2007; 14(4): 453–62. https://doi.org/10.1016/j.jmig.2007.01.013
24. Strowitzki T. Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction. 2010; 25(3): 633–41. https://doi.org/10.1093/humrep/dep469
25. Miyashita M., Koga K., Takamura M., Izumi G., Nagai M. et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecological Endocrinology. 2014; 30(9): 644–8. https://doi.org/10.3109/09513590.2014.911279
26. Yamanaka K., Xu B., Suganuma I., Kusuki I., Mita S., Shimizu Y., et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil steril. 2012; 97(2): 477–82. https://doi.org/10.1016/j.fertnstert.2011.11.005

27. Ярмолинская М.И., Флорова М.С. Возможности терапии диеногестом 2 мг у больных наружным генитальным эндометриозом. Проблемы репродукции. 2017; 23(1): 70–9.

28. McKinnon B.D., Bertschi D., Bersinger N.A., Mueller M.D. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015; 26(1): 1–10. https://doi.org/10.1016/j.tem.2014.10.003
29. Mita S., Shimizu Y., Sato A., Notsu T., Imada K., Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil steril. 2014; 101(2): 595–601. https://doi.org/10.1016/j.fertnstert.2013.10.038
30. Osuga Y., Watanabe M., Hagino A. Long‐term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obst Gynaecol Research. 2017; 43(9): 1441–8. https://doi.org/10.1111/jog.13406
31. Fawzy M., Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015; 292(6): 1267–71. https://doi.org/10.1007/s00404-015-3755-5
32. Neriishi K., Hirata T., Fukuda S., Izumi G., Nakazawa A., Yamamoto. Long‐term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Research. 2018; 44(8): 1439–44. https://doi.org/10.1111/jog.13674
33. Prathoomthong S., Prathoomthong S., Tingthanatikul Y., Lertvikool S., Rodratn N., Waiyaput W., et al. The effects of dienogest on macrophage and natural killer cells in adenomyosis: a randomized controlled study. Int J Fertil Steril. 2018; 11(4): 279–86. doi: 10.22074/ijfs.2018.5137.
34. Vercellini P., Vigano P., Somigliana E., Daguati R., Abbiati A., Fedele. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4): 465–77. https://doi.org/10.1016/j.bpobgyn.2006.01.017
35. Bromley B., Shipp T. D., Benacerraf B. Adenomyosis: sonographic findings and diagnostic accuracy. J Ultrasound Med. 2000; 19(8): 529–34. https://doi.org/10.7863/jum.2000.19.8.529

36. Айламазян Э.К., Ярмолинская М.И., Молотков А.С., Цицкарава Д.З. Классификации эндометриоза. Журнал акушерства и женских болезней. 2017; 66(2): 77–92.

37. Pistofidis G., Makrakis E., Koukoura O., Bardis N., Balinakos P., Anaf V. Distinct types of uterine adenomyosis based on laparoscopic and histopathologic criteria. Clin Experiment Obstet Gynecol. 2014; 41(2): 113–8.
38. Kunz G., Beil D., Huppert P., Noe M., Kissler S., Leyendecker G. Adenomyosis in endometriosis—prevalence and impact on fertility. Evidence from magnetic resonance imaging. Human Reproduction. 2005; 20(8): 2309–16. https://doi.org/10.1093/humrep/dei021
39. Vercellini P., Consonni D., Dridi D., Bracco B., Frattaruolo M. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Human Reproduction. 2014; 29(5): 964–77. https://doi.org/10.1093/humrep/deu041
40. Razavi M., Maleki-Hajiagha A., Sepidarkish M., Rouholamin S., Almasi-Hashiani A., Rezaeinejad M. Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. Int J Gynaecol Obstet. 2019; 145(2): 149–57. doi: 10.1002/ijgo.12799

Поступила 06.02.2020

Принята в печать 07.02.2020